Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 168-176

  Peter, Katrin ^a   Gambertoglio, John G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; ZIDOVUDINE; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE 5' TRIPHOSPHATE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESISTANCE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; MUTATION; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; AREA UNDER CURVE; CELL SEPARATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; NUCLEOTIDES; P-GLYCOPROTEIN; PHOSPHATES; PHOSPHORYLATION; RADIOIMMUNOASSAY; TIME FACTORS; ZIDOVUDINE;

EID: 0029909226     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90132-0     Document Type: Article

References (23)

1. Zimmerman TP, Mahony WB, Prus KL. 3′-Azido-3′-deoxythymidine: an unusual nucleoside analog that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 1987;262:5748-54.
2. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
3. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
4. Smith M, Salomon H, Wainberg MA. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clin Invest Med 1994;17:226-43.
5. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
6. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
7. Gollapudi S, Gupta S. Human immunodeficiency virus 1-induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990;171:1002-7.
8. Gupta S, Gollapudi S. P-Glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301.
9. Antonelli G, Turriziani O, Cianfriglia M, Riva E, Dong G, Fattorossi A, et al. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses 1992;8:1839-44.
10. Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 1992;29:413-29.
11. Hill MD, Miles S, Gomperts E, Holcenberg JS, Woods L, Avramis VI. Decreased activation of zidovudine (AZT) in peripheral blood lymphocytes from patients with AIDS chronically treated with AZT. Seventh International Conference on AIDS, Florence, Italy, June 16-21, 1991.
12. Avramis VI, Kwock R, Solorzano MM, Gomperts E. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993; 6:1287-96.
13. Wu S, Liu X, Solorzano MM, Kwock R, Avramis VI. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:1-9.
14. Peter K, Gambertoglio JG. Quantification of zidovudine (ZDV) and individual ZDV phosphates in peripheral blood mononuclear cells (PBMCs) by a combined isocratic high performance liquid chromatography (HPLC) radioimmunoassay (RIA) method. J Pharm Biomed Anal 1996;14:491-9.
15. Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, Lietman PS. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography radioimmunoassay procedure. Antimicrob Agents Chemother 1992;36:2473-7.
16. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994;38:115-21.
17. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1541-7.
18. Barry M, Wild M, Veal G, Back D, Breckenridge A, Fox A, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994;8:F1-5.
19. Balzarini J, Pauwels R, Baba M, Herdewijn P, De Clercq E, Border S, et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988;37:897-903.
20. Dianzani F, Antonelli G, Turriziani O, Riva E, Simeoni E, Signoretti C, et al. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994;10:1471-8.
21. Toernevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. Cytotoxicity of 3′-azidothymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 1995;49: 829-37.
22. Bridges EG, Faraj A, Sommadossi JP. Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993;45:1571-6.
23. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.